You are here
Post-market review of home-use foetal dopplers
The Therapeutic Goods Administration (TGA) has undertaken a post-market review of all home-use foetal dopplers included in the Australian Register of Therapeutic Goods (ARTG).
Previously, we published a safety alert about home-use foetal dopplers.
Home-use foetal dopplers
Foetal dopplers are handheld devices used to detect or monitor the heartbeat of a baby during pregnancy. These are commonly used by health professionals during prenatal visits. In recent years, foetal dopplers for home-use have become widely available for members of the public.
Background of the review
We received reports where expectant parents may have been falsely reassured by using home-use foetal dopplers and delayed seeking medical attention. Untrained users could mistake the sounds of the mother's heartbeat or placental sounds for the baby's heartbeat. This could potentially delay expectant parents from seeking necessary medical care.
In response to the reports, we reviewed all home-use foetal dopplers included in the Australian Register of Therapeutic Goods (ARTG).
The purpose of the review was to determine whether the risk of using these devices outweighed the potential benefit.
Post-market review: overview
We required all sponsors of home-use foetal dopplers included in the ARTG to provide information to the TGA about their product, including:
- Advertising material
- Labelling information including the Instructions for Use (IFU)
- Complaint and adverse event information
- Risk-benefit analysis, and
- Clinical data supporting the use of their device.
During the review, the TGA followed guidelines from The Royal Australian and New Zealand College of Obstetricians and Gynaecologists (RANZCOG). We also sought expert advice from the Advisory Committee for Medical Devices (ACMD). The ACMD advised that the overall risk of inaccurately using the device outweighs the benefits and recommended limiting the supply of the device to appropriately trained health professionals.
All regulatory decisions taken during this post-market review were made on an individual device basis and were based on the evidence submitted by sponsors and manufacturers, and expert advice.
Post-market review: outcomes and actions
All home-use foetal dopplers that were intended to be used without the supervision of a healthcare professional have been removed from the ARTG. The review confirmed that the lack of specialised training to use these devices could result in false reassurance of the health of a baby.
Where a foetal doppler device is cancelled from the ARTG, they are not being recalled from the market. The cancellation means home-use devices will no longer be available for purchase. However, there may be resale of second-hand devices.
Information for consumers
Expectant parents should seek immediate medical attention if they are worried about their baby. They should NOT rely on home-use foetal dopplers for reassurance.
Consumers who are considering these devices should make an informed decision and be aware of the potential risks associated with the home-use devices.
Consumers are also recommended to talk to their healthcare provider before using a home-use foetal doppler.
Information for healthcare professionals
Healthcare professionals are advised to caution expectant parents about the potential risk of using home-use foetal dopplers.
The TGA is urging consumers and health professionals to report any suspected adverse events where a home-use foetal doppler may have been a contributing factor.
Regulatory decisions
During the post-market review, some sponsors decided to discontinue supplying their products to the Australian market. A sponsor may do this at any time and a reason for their withdrawal from the market is not required to be provided to us.
We decided to cancel all remaining home-use foetal dopplers supplied in Australia.
The below table reflects the status of ARTG entries for devices included in the post‑market review.
ARTG | Sponsor | Manufacturer | Device/product name | Outcome/action | Date effective |
---|---|---|---|---|---|
371112 | Sean Stephen Lowson | Shenzhen Jumper Medical Equipment Co Ltd | Foetal Doppler system | Sponsor initiated cancellation | 12 July 2022 |
397660 | Macquarie Medical Systems Pty Ltd | Edan Instruments Inc | Foetal Doppler system | Sponsor initiated cancellation | 5 October 2022 |
373423 | Snotty Noses Pty Ltd | Shenzhen Jumper Medical Equipment Co Ltd | Foetal Doppler system | Cancelled by the TGA | 23 December 2022 |
236029 | Snotty Noses Pty Ltd | Shenzhen Jumper Medical Equipment Co Ltd | Foetal Doppler system | Sponsor initiated cancellation | 27 July 2023 |
277143 | ESHOPPING GROUP PTY LTD | Shenzhen Jumper Medical Equipment Co Ltd | Foetal Doppler system | Sponsor initiated cancellation | 21 August 2023 |
382476 | ESHOPPING GROUP PTY LTD | Bistos Co Ltd | Foetal Doppler system | Sponsor initiated cancellation | 21 August 2023 |
224685 | AJ Harry | Shenzhen Jumper Medical Equipment Co Ltd | Foetal Doppler system | Cancelled by the TGA | 1 September 2023 |
316781 | Le Reve HealthCare Pty Ltd (AKA Caremax) | Shenzhen Jumper Medical Equipment Co Ltd | Foetal Doppler system | Cancelled by the TGA | 6 October 2023 |
197126 | Device Technologies Australia Pty Ltd | Shenzhen Aeon Technology Co Ltd | Foetal heart detector, ultrasonic | Sponsor initiated cancellation | 25 June 2024 |
212739 | Cabrini Health | Shenzhen Jumper Medical Equipment Co Ltd | Foetal heart detector, ultrasonic | Sponsor initiated cancellation | 29 July 2024 |
311986 | Heramed Limited | HeraMED Ltd | Foetal Doppler system | Cancelled by the TGA | 27 September 2024 |
265555 | Laerdal Pty Ltd | Laerdal Medical AS | Foetal Doppler system | Sponsor initiated cancellation | 3 October 2024 |
Note: An ARTG entry may be cancelled in two ways: (1) The sponsor (the supplier within Australia) may voluntarily cancel the entry or (2) the TGA may cancel the entry. The sponsor can cancel their entry at any time and is not required to provide a reason to the TGA.
Baby Movement Apps
There are apps and other software on the market for recording diaries, or monitoring baby movements or kicks during pregnancy. These products are widely available for download by consumers. It may look like a diary, but these digital products are intended to prevent foetal harm through monitoring foetal movement. As such they are considered to be medical devices. These must be included in ARTG.
There is a risk of false reassurance to consumers once the movements are recorded in such an app. While the developer may not claim to take action, this false reassurance may lead people to not seek medical attention right away.
Expectant mothers should go to a healthcare facility if they are worried.
Reporting problems
In addition to adverse events involving home-use foetal dopplers, we encourage consumers and health professionals to report problems with medical devices. Your report will contribute to the TGA's monitoring of these products. See the TGA Incident Reporting and Investigation Scheme (IRIS).
The TGA cannot give advice about an individual's medical condition. We recommend talking to a doctor is you are worried about an adverse event.
Key information for stakeholders
-
Meeting statementsAdvisory Committee on Medical Devices meeting statement, Meeting 68, 11 August 2022
-
Safety alertsThe TGA has become aware of instances where patients have become falsely reassured by the home use fetal dopplers and delayed medical attention.
-
PageReporting adverse events (side effects to medicines and problems with medical devices) helps make medicines and medical devices safer for everyone.
-
Reference materialQuestions and answers about the Medical device Incident Reporting and Investigation Scheme
Version history
Version | Description of change | Author | Effective date |
V1.2 | Additional information added and table updated | Devices Post Market Review Section (DPMRS) | September 2024 |
V1.1 | Table updated and baby movement app information added | Devices Post Market Review Section (DPMRS) | August 2023 |
V1.0 | Original publication | Devices Post Market Review Section (DPMRS) | May 2023 |